MNOV

$MNOV chatter on StockTwits

• 
  jorge .miguel@focafoca995d

  $MNOV held its 2026 annual meeting, with shareholders approving BDO USA as the independent auditor and voting on other proposals.

  View on StockTwits ↗
• 
  Stackingg@StackinggBullish5d

  $MNOV

  View on StockTwits ↗
• 
  FJ@pirowanJun 10

  @mfglola Have you been tracking $MNOV? They are currently conducting an ALS Phase 3 trial. They optimized this P3 trial design by targeting a specific patient sub-population that showed efficacy in Phase 2. It’s a 12-month double-blind study. Patient enrollment was completed in Sept 2025, with top-line data expected by late 2026.

  View on StockTwits ↗
• 
  Albert De Beaulieu@YearOfTheRabbitBullishJun 8

  $MNOV such an exciting stock I bought such amazing movement

  View on StockTwits ↗
• 
  DARKP00L@DARKP00LJun 8

  $MNOV 08:07 on Jun. 08 2026 MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma #tradeideas

  View on StockTwits ↗
• 
  FJ@pirowanMay 31

  @LXP @Mulhollandr @neuroinvestor3 Another major issue is the breakdown of dose-response. They claim a 70-90%+ survival risk reduction for the 30mg group. Yet, the concurrently tested 60mg group showed absolutely zero survival benefit. ​This inverse dose-response strongly suggests the localized 30mg survival signal isn't a true drug effect, but simply statistical noise generated by extremely few events. I believe this is definitive proof that Clene's survival data is a statistical illusion. ​Don't get me wrong—I actually have high hopes for CNM-Au8's potential. However, a rigorous Phase 3 trial is necessary to prove it. I believe MediciNova's ($MNOV) MN-166 is currently the closest to approval in the ALS space. Since their mechanisms of action (MoA) do not overlap, once CNM-Au8 clears a P3, it could potentially become the ultimate combination therapy with MN-166.

  View on StockTwits ↗
• 
  FJ@pirowanMay 30

  Looking ahead to $MNOV’s upcoming Ph2 NATG-202 topline data for NAFLD/T2DM (expected Q3), the setup is highly compelling based on pure data and biology. ​In the previous Ph2, tipelukast achieved a massive 50.8% triglyceride (TG) reduction in T2DM patients (p=0.00006). This current trial is enriched specifically for these top-responding T2DM patients, using a full 500mg dose for 24 weeks. ​Given that liver fat in NAFLD is literally accumulated TG, it is biologically counterintuitive to think liver fat won’t drop when blood TG is being crushed this drastically. With a 24-week timeline—plenum of time to see structural changes—expectations for the co-primary endpoints (TG and CAP score for liver fat) are exceptionally well-grounded.

  View on StockTwits ↗
• 
  FJ@pirowanMay 27

  $MNOV Today's IR confirmed that Last Patient Last Visit (LPLV) is complete for $MNOV's NAFLD trial targeting Type 2 Diabetes (T2DM) patients. ​Keep in mind, a previous small P2 already crushed the triglyceride (TG) reduction endpoint (p<0.0001). This time, they’ve enriched the trial by specifically targeting T2DM patients, the exact subgroup that showed the most massive TG drops in the past data. ​With the TG reduction essentially a given, the real key to watch is the co-primary endpoint: how much it reduces liver fat (CAP score). Furthermore, if we see any exploratory trends indicating fibrosis improvement, this could be absolutely massive.

  View on StockTwits ↗
• 
  FJ@pirowanMay 26

  $MNOV Ghost town in here. The market is completely sleeping on $MNOV. Nobody seems to care that we have three massive readouts coming up: NAFLD P2 in the summer, plus CIPN P2 and ALS P3 by year-end. ​Keep in mind, NAFLD and CIPN already posted solid results in their previous small P2a trials, so these are essentially confirmation runs. As for ALS, they are running a full 234-patient P3 specifically enriched with the responder profile from their past P2. Expectations should be high. ​Yet, the current valuation is priced for absolute zero, assuming every single trial will fail. The risk/reward skew at these levels is mind-boggling.

  View on StockTwits ↗
• 
  SuperGreenToday@SuperGreenTodayMay 25

  $MNOV Share Price: $1.39 Contract Selected: Jan 15, 2027 $7.5 Calls Buy Zone: $0.11 – $0.14 Target Zone: $0.21 – $0.25 Potential Upside: 70% ROI Time to Expiration: 234 Days | Updates via https://fxcapta.com/stockinfo/

  View on StockTwits ↗
• 
  FJ@pirowanMay 25

  @Dopamineaddict Interesting take on $ANVS, but pivoting to a late-stage ALS trial from scratch is a multi-year process. Looking at the broader ALS space, MediciNova ($MNOV) is an interesting comparison. ​Like Buntanetap, studies show MN-166 also promotes clearance of TDP-43 aggregates. Beyond that, MN-166 fully crosses the BBB to directly shut down microglial neuroinflammation via MIF/PDE inhibition, attacking from two angles. ​The biggest difference is the timeline. An $ANVS pivot needs years for trial design and enrollment. Meanwhile, $MNOV is already fully enrolled in a 234-patient Phase 3 (COMBAT-ALS), measuring hard clinical endpoints (ALSFRS-R/survival) instead of just surrogate biomarkers. ​With $MNOV topline data dropping by year-end, it’ll be interesting to see how the market prices a near-term P3 completion vs an early-stage pivot. Worth watching.

  View on StockTwits ↗
• 
  FJ@pirowanMay 25

  @Dopamineaddict ​I think both $CLNN and $COYA are solid plays, but shifting gears for a second—what are everyone’s thoughts on MediciNova ($MNOV) and their ALS trial? ​Their end goal is similar to COYA’s approach (halting neuroinflammation), but MN-166 is a small molecule that fully crosses the BBB to directly silence microglia in the brain. The MoA is just much more direct. ​What’s huge here is that they aren't just relying on early biomarker pilot studies. They are currently running a full 234-patient Phase 3, backed by robust responder analysis from their previous P2. ​Topline data is dropping by the end of this year. Yet, because the market is so obsessed with early-stage biomarker hype right now, this near-completion P3 play is flying completely under the radar. Doesn't this current valuation seem completely absurd to anyone else?

  View on StockTwits ↗
• 
  June c@JunecareMay 7

  $MNOV Last night, the MNOV stock jumped to $9 for a minute. Almost an hour later, it was above $5, then, seemingly out of nowhere, dropped back to $1.43/5. Once was a glitch, twice is what?

  View on StockTwits ↗
• 
  June c@JunecareMay 7

  $MNOV hier soir l action est monté à 9 dollars d' un coup pendant 1 min Presque une heure après cette fois ci elle montre plus de 5 dollars ,puis l. Air de rien revient au cours de 1,43/5 . Une fois c un bug ,deux fois c est quoi??

  View on StockTwits ↗
• 
  laaarsas@laaarsasApr 28

  $MNOV This is something to stay away from right?

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.